Bird Flu Sparks Vaccine Stock Surge: ETFs To Watch As H5N1 Outbreak Intensifies
Bird Flu Sparks Vaccine Stock Surge: ETFs To Watch As H5N1 Outbreak Intensifies
禽流感引發生物-疫苗股票激增：隨着H5N1疫情加劇，值得關注的ETF
The U.S. reported its first human death from the H5 bird flu strain this week, causing a spike in vaccine developer stocks Moderna (NASDAQ:MRNA), Novavax (NASDAQ:NVAX), CureVac (NASDAQ:CVAC) and Pfizer (NYSE:PFE).
本週，美國報告了首例H5禽流感病毒株的人類死亡案例，這導致了疫苗開發商Moderna（納斯達克：MRNA）、諾瓦瓦克斯醫藥（納斯達克：NVAX）、CureVac（納斯達克：CVAC）和輝瑞（紐交所：PFE）的股票飆升。
Vaccine production efforts are ramping up as health officials monitor the outbreak closely. In an update on Monday, CDC said there have been 66 confirmed cases in the U.S. in the 2024 outbreak.
隨着衛生官員密切關注疫情，疫苗生產工作正在加速。根據週一的更新，CDC表示在2024年的疫情中，美國已有66例確診病例。
CDC said the public risk remains low. Bird flu has severely impacted poultry farms and cattle herds across 16 states, marking the worst outbreak of its kind.
CDC表示，公衆風險仍然較低。禽流感已嚴重影響到16個州的家禽養殖場和牛群，標誌着該類疫情的最嚴重爆發。
Vaccine Providers in the Limelight
疫苗供應商受到關注
In the...
在美...
登入免費觀看全文
登入/註冊
熱門討論
中概股財報季火熱：驚喜盈利能否延續漲勢？
1. 哪些行業可能成為本輪財報季的市場焦點？ 2. 在政府強調科技創新和可持續發展的背景下，你認為哪些行業具有最大的增長潜力？
Moomoo News Global
03/04 23:26
中國兩會：會議前後股票價格變動的關鍵要點